Predicting individual-specific cardiotoxicity responses induced by tyrosine kinase inhibitors
暂无分享,去创建一个
M. Birtwistle | C. Schaniel | E. Sobie | E. Azeloglu | G. Jayaraman | Bin Hu | N. Dubois | Jaehee V. Shim | Y. Xiong | R. Dariolli | Ravi Iyengar | Priyanka Dhanan | Yuguang Xiong | Gomathi Jayaraman
[1] A. Tveito,et al. Validating the Arrhythmogenic Potential of High-, Intermediate-, and Low-Risk Drugs in a Human-Induced Pluripotent Stem Cell-Derived Cardiac Microphysiological System. , 2022, ACS Pharmacology & Translational Science.
[2] Evan W. Miller,et al. Metabolically driven maturation of human-induced-pluripotent-stem-cell-derived cardiac microtissues on microfluidic chips , 2022, Nature Biomedical Engineering.
[3] M. Mahajan,et al. A library of induced pluripotent stem cells from clinically well-characterized, diverse healthy human individuals , 2020, bioRxiv.
[4] Amanda J. Pickard,et al. Transcriptomic profiling of human cardiac cells predicts protein kinase inhibitor-associated cardiotoxicity , 2020, Nature Communications.
[5] G. Norman,et al. Limitations of Animal Studies for Predicting Toxicity in Clinical Trials: Is it Time to Rethink Our Current Approach? , 2019 .
[6] Gail A. Van Norman,et al. Limitations of Animal Studies for Predicting Toxicity in Clinical Trials , 2019, JACC. Basic to translational science.
[7] G. Gintant,et al. Use of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes in Preclinical Cancer Drug Cardiotoxicity Testing: A Scientific Statement From the American Heart Association. , 2019, Circulation research.
[8] Karoline Horgmo Jæger,et al. Improved Computational Identification of Drug Response Using Optical Measurements of Human Stem Cell Derived Cardiomyocytes in Microphysiological Systems , 2019, bioRxiv.
[9] Sarah A. Boswell,et al. Adaptation of Human iPSC-Derived Cardiomyocytes to Tyrosine Kinase Inhibitors Reduces Acute Cardiotoxicity via Metabolic Reprogramming. , 2019, Cell systems.
[10] Daniel C Millard,et al. International Multisite Study of Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Drug Proarrhythmic Potential Assessment , 2018, Cell reports.
[11] A. Tveito,et al. Inversion and computational maturation of drug response using human stem cell derived cardiomyocytes in microphysiological systems , 2018, bioRxiv.
[12] W. Giles,et al. Pro-arrhythmic effects of low plasma [K+] in human ventricle: An illustrated review. , 2017, Trends in cardiovascular medicine.
[13] M. Birtwistle,et al. Mechanistic Systems Modeling to Improve Understanding and Prediction of Cardiotoxicity Caused by Targeted Cancer Therapeutics , 2017, Front. Physiol..
[14] E. Sobie,et al. Population-based mechanistic modeling allows for quantitative predictions of drug responses across cell types , 2017, bioRxiv.
[15] Kevin R. DeMarco,et al. A multiscale computational modelling approach predicts mechanisms of female sex risk in the setting of arousal‐induced arrhythmias , 2017, The Journal of physiology.
[16] Zhilin Qu,et al. Electrophysiology of Hypokalemia and Hyperkalemia. , 2017, Circulation. Arrhythmia and electrophysiology.
[17] Praveen Shukla,et al. High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells , 2017, Science Translational Medicine.
[18] R. Iyengar,et al. A Comparison of mRNA Sequencing with Random Primed and 3′-Directed Libraries , 2017, bioRxiv.
[19] I. Abraham,et al. Comparative Effectiveness of Newer Tyrosine Kinase Inhibitors Versus Imatinib in the First-Line Treatment of Chronic-Phase Chronic Myeloid Leukemia Across Risk Groups: A Systematic Review and Meta-Analysis of Eight Randomized Trials. , 2016, Clinical lymphoma, myeloma & leukemia.
[20] Russ B Altman,et al. Human induced pluripotent stem cell–derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity , 2016, Nature Medicine.
[21] H. Gharwan,et al. Kinase inhibitors and monoclonal antibodies in oncology: clinical implications , 2016, Nature Reviews Clinical Oncology.
[22] Thomas Streichert,et al. Analysis of Tyrosine Kinase Inhibitor-Mediated Decline in Contractile Force in Rat Engineered Heart Tissue , 2016, PloS one.
[23] T. Colatsky,et al. A New Perspective in the Field of Cardiac Safety Testing through the Comprehensive In Vitro Proarrhythmia Assay Paradigm , 2016, Journal of biomolecular screening.
[24] M. Ewer,et al. Cardiotoxicity of anticancer treatments , 2015, Nature Reviews Cardiology.
[25] A. Lindahl,et al. Identification of novel biomarkers for doxorubicin-induced toxicity in human cardiomyocytes derived from pluripotent stem cells , 2015, Toxicology.
[26] Kwang-Hyun Cho,et al. The switching role of β-adrenergic receptor signalling in cell survival or death decision of cardiomyocytes , 2014, Nature Communications.
[27] H. Geys,et al. The concordance between nonclinical and phase I clinical cardiovascular assessment from a cross-company data sharing initiative. , 2014, Toxicological sciences : an official journal of the Society of Toxicology.
[28] Nima Milani-Nejad,et al. Small and large animal models in cardiac contraction research: advantages and disadvantages. , 2014, Pharmacology & therapeutics.
[29] S. Severi,et al. Computational Models of Ventricular- and Atrial-Like Human Induced Pluripotent Stem Cell Derived Cardiomyocytes , 2013, Annals of Biomedical Engineering.
[30] Kevin A Janes,et al. Models of signalling networks – what cell biologists can gain from them and give to them , 2013, Journal of Cell Science.
[31] Gary R. Mirams,et al. mRNA Expression Levels in Failing Human Hearts Predict Cellular Electrophysiological Remodeling: A Population-Based Simulation Study , 2013, PloS one.
[32] M. Suematsu,et al. Distinct metabolic flow enables large-scale purification of mouse and human pluripotent stem cell-derived cardiomyocytes. , 2013, Cell stem cell.
[33] Thomas R. Gingeras,et al. STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..
[34] R. Hajjar,et al. Altered sarcoplasmic reticulum calcium cycling—targets for heart failure therapy , 2012, Nature Reviews Cardiology.
[35] Jeffrey J Saucerman,et al. Network Reconstruction and Systems Analysis of Cardiac Myocyte Hypertrophy Signaling* , 2012, The Journal of Biological Chemistry.
[36] R. Iyengar,et al. Merging Systems Biology with Pharmacodynamics , 2012, Science Translational Medicine.
[37] Jochen H M Prehn,et al. Clinical application of a systems model of apoptosis execution for the prediction of colorectal cancer therapy responses and personalisation of therapy , 2011, Gut.
[38] Gordon Keller,et al. SIRPA is a specific cell-surface marker for isolating cardiomyocytes derived from human pluripotent stem cells , 2011, Nature Biotechnology.
[39] Ravi Iyengar,et al. Systems Biology—Biomedical Modeling , 2011, Science Signaling.
[40] Gordon Keller,et al. Stage-specific optimization of activin/nodal and BMP signaling promotes cardiac differentiation of mouse and human pluripotent stem cell lines. , 2011, Cell stem cell.
[41] K. Kolaja,et al. Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes , 2011, Nature Reviews Drug Discovery.
[42] F. Vogenberg,et al. Personalized medicine: part 1: evolution and development into theranostics. , 2010, P & T : a peer-reviewed journal for formulary management.
[43] Mark D. Robinson,et al. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data , 2009, Bioinform..
[44] J. Rice,et al. Approximate model of cooperative activation and crossbridge cycling in cardiac muscle using ordinary differential equations. , 2008, Biophysical journal.
[45] Eric D. Adler,et al. Human cardiovascular progenitor cells develop from a KDR+ embryonic-stem-cell-derived population , 2008, Nature.
[46] R. Shah,et al. Refining detection of drug-induced proarrhythmia: QT interval and TRIaD. , 2005, Heart rhythm.
[47] T. Fleming,et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.
[48] Ennis,et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.
[49] I. Cohen,et al. Tyrosine kinase inhibition reduces if in rabbit sinoatrial node myocytes , 1997, Pflügers Archiv.